Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study. While a 2006 report from members of the same study team found that treatment with gonadotropin-releasing hormone agonists increased the risk of diabetes and heart disease, the current study is the first to examine whether treatment actually increased heart disease-related deaths.